YTYee Lin Thong

Yee Lin Thong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yee Lin Thong has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Platelet triggering receptor expressed on myeloid cells–like transcript 1 regulation in healthy donors and patients at risk of bleeding and thrombosis

    by Amandeep Kaur, Sidra A. Ali, Marcus Alim, Ziliang R. Chen, Vijay Bhoopalan, Samantha J. Montague, Yee Lin Thong, Mikhail Danilov, Justin J. Xia, Jordan Ross, et al.

  • Open Access

    Platelet dysfunction in immune thrombocytopenia: Finding clinical subsets with platelet phenotypes

    by Sidra A. Ali, Sarah M. Hicks, Lucy A. Coupland, Simone A. Brysland, Vijay Bhoopalan, Yee Lin Thong, Amandeep Kaur, Robert K. Andrews, Elizabeth E. Gardiner, Philip Y.‐I. Choi

    Summary: Patients with immune thrombocytopenia (ITP) remain a challenge to diagnose, manage and predict bleeding risk. A comprehensive assessment of platelet function may aid clinical management. This study assessed platelet parameters to predict bleeding in ITP. Blood from 103 clinically annotated cases with isolated thrombocytopenia and 123 healthy donors was evaluated. In the ITP cohort, 75/110 encounters (68%) had platelet counts below 50 × 10 9 /L. Platelet surface proteins, reticulated platelets and activation were quantified using flow cytometry. Soluble receptor fragments, citrullinated histone‐DNA (CitH3‐DNA) complexes and thrombopoietin (TPO) were quantified by enzyme‐linked immunosorbent assay (ELISA). Whole blood clotting and platelet contribution to clot formation were evaluated using viscoelastography. Elevated levels of glycoprotein (GP) VI ( p = 0.0012), Trem‐like transcript‐1 (TLT‐1) ( p = 0.0248), platelet‐bound immunoglobulin (Ig) G ( p < 0.0029), CitH3‐DNA complexes ( p = 0.0022), TPO ( p < 0.0001) and reduced platelet contribution to clot formation ( p < 0.0001) were observed in primary ITP patients with bleeding and bruising symptoms. A multivariable analysis revealed that measuring platelet indices strengthened a predictive bleeding model over platelet count alone (78.1% vs. 70.48%). Symptomatic ITP patients have measurable platelet dysfunction and quantifiable differences on platelet surface, increased evidence of NETosis and elevated TPO levels. Identifying biomarkers for ITP outcomes can define subsets of disease with clinical relevance.


  • Open Access

    Patients with Waldenström macroglobulinemia have impaired platelet and coagulation function

    by Simone A. Brysland, Dipti Talaulikar, Sarah M. Hicks, James I. Hearn, Sidra A. Ali, Muhammad Gohar Maqbool, Mridula Mokoonlall, Vijay Bhoopalan, Amandeep Kaur, Yee Lin Thong, et al.

    Clinical features in patients with the B-cell lymphoma, Waldenström macroglobulinemia (WM), include cytopenias, immunoglobulin M (IgM)–mediated hyperviscosity, fatigue, bleeding, and bruising. Therapeutics such as Bruton's tyrosine kinase inhibitors (BTKis) exacerbate bleeding risk. Abnormal hemostasis arising from platelet dysfunction, altered coagulation or vascular impairment have not yet been investigated in patients with WM. Therefore, this study aimed to evaluate hemostatic dysfunction in samples from these patients. Whole blood (WB) samples were collected from 14 patients with WM not receiving therapy, 5 patients receiving BTKis and 15 healthy donors (HDs). Platelet receptor levels and reticulation were measured by flow cytometry, plasma thrombin generation with or without platelets by fluorescence resonance energy transfer assay, WB clotting potential by rotational thromboelastometry, and plasma soluble glycoprotein VI (sGPVI) and serum thrombopoietin (TPO) by enzyme-linked immunosorbent assay. Donor platelet spreading, aggregation, and ability to accelerate thrombin generation in the presence of WM-derived IgM were assessed. WM platelet receptor levels, responses to physiological agonists, and plasma sGPVI were within normal ranges. WM platelets had reduced reticulation (P = .0012) whereas serum TPO levels were increased (P = .0040). WM plasma displayed slower thrombin generation (P = .0080) and WM platelets contributed less to endogenous thrombin potential (ETP; P = .0312). HD plasma or platelets incubated with IgM (50-60 mg/mL) displayed reduced spreading (P = .0002), aggregation (P < .0001), and ETP (P = .0081). Thus, alterations to thrombin potential and WB coagulation were detected in WM samples. WM IgM significantly impaired hemostasis in vitro. Platelet and coagulation properties are disturbed in patients with well-managed WM.